Georgia

DataOceans Moves Corporate Headquarters to Alpharetta, GA

Retrieved on: 
Sunday, December 12, 2021
CEO, Organization, Oceanus, LinkedIn, SMS, Restaurant, Duke Diet and Fitness Center, Growth, Heart, Center, Georgia, CCM, Marketing, Technology

The brand new, modern office environment includes a combination of open workspaces and hotel options to foster enhanced collaboration among team members.

Key Points: 
  • The brand new, modern office environment includes a combination of open workspaces and hotel options to foster enhanced collaboration among team members.
  • Larry Buckley, DataOceans founding partner and CEO "DataOceans is very excited about our current growth trajectory and our resulting move to the Georgia 400 Center in Alpharetta.
  • The DataOceans Oceanus platform enables organizations to unlock customer data from existing systems to create and deliver highly personalized and compelling communications.
  • DataOceans enables clients to transform how they engage with customers, innovate how they do business, and simplify their technology landscape.

New Data at ASH21, Published in NEJM Further Demonstrate beti-cel as a Potentially Curative One-Time Gene Therapy for β-thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable TI and Normal or Near-Normal Adult Hb Levels

Retrieved on: 
Saturday, December 11, 2021
Biotechnology, Health, Genetics, Clinical Trials, Oncology, Cell, Malignancy, Center for Cell and Gene Therapy, SAE, TI, Pulmonary embolism, Tachycardia, Breathe Me, Thrombocytopenia, Neutropenia, Risk, MPH, Health, Mortal Kombat, Lists of diseases, Congress Center, History, Adult, Disease, Â, Adolescence, AES, Infertility, Erythropoiesis, Phlebotomy, Doctor of Philosophy, Subclinical infection, ASH, Achievement, Department, Exposition, Gene therapy, AE, Iron, The New England Journal of Medicine, Pain, Mortality, Infection, Quality of life (healthcare), Society, HB, Georgia, Gallbladder disease, Betibeglogene autotemcel, Patient, Depression, Georgia World Congress Center, Anemia, Iron overload, Abdominal pain, Bluebird bio, Pediatrics, Gallstone, RBC, Leukopenia, Profile, Diabetic ketoacidosis, Northstar, Cytopenia, Pharmaceutical industry, Medical imaging, Vaccine, Medicine, betibeglogene autotemcel (beti-cel), bluebird bio, Inc., BETIBEGLOGENE AUTOTEMCEL (BETI-CEL), BLUEBIRD BIO, INC.

beti-cel enables the production of healthy adult hemoglobin, which may offer patients freedom from lifelong red blood cell transfusions.

Key Points: 
  • beti-cel enables the production of healthy adult hemoglobin, which may offer patients freedom from lifelong red blood cell transfusions.
  • Transfusion-dependent beta-thal is a severe genetic disease caused by mutations in the -globin gene, which may cause significantly reduced or absent adult hemoglobin (Hb) production.
  • This can result in severe anemia and lifelong dependence on RBC transfusions, a lengthy process that patients typically undergo every 3-4 weeks.
  • Once patients have the A-T87Q-globin gene, the HSCs have the potential to produce gene therapy-derived adult Hb (HbAT87Q) at levels that can eliminate the need for transfusions.

Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition

Retrieved on: 
Saturday, December 11, 2021
Research, FDA, Genetics, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, FDA, Stroke, Gene editing, Sickle, Securities Exchange Act of 1934, HBA, Risk, Acute chest syndrome, U.S. Securities and Exchange Commission, Birmingham, Congress Center, Food, Medicine, Nasdaq, HSC, Association, Adult, Disease, SCD, Mutation, Clinical trial, Graft-versus-host disease, Goal, ASH, Securities Act of 1933, American Association, Lists of diseases, Safety, Drug Quality and Security Act, Mortality, Bio, Georgia, Cryopreservation, HBS, Gene, Graphite, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Poster, Brain, Georgia World Congress Center, Sickle cell disease, Patient, Anemia, Kidney, University, Heart, Life expectancy, Cas9, A Call for Unity, Liver, DNA, Genome, End organ damage, HDR, Health, Pharmaceutical industry, Medical device, Antibiotics, Sickle Cell Disease (SCD), GPH101, Graphite Bio, SICKLE CELL DISEASE (SCD), GPH101, GRAPHITE BIO

While allogeneic transplant is the only available cure for sickle cell disease, the procedure has several limitations, mainly lack of available donors and risk of graft-versus-host disease.

Key Points: 
  • While allogeneic transplant is the only available cure for sickle cell disease, the procedure has several limitations, mainly lack of available donors and risk of graft-versus-host disease.
  • As an investigator in the CEDAR trial, I look forward to assessing GPH101s potential to be a curative option for patients.
  • The CEDAR trial is an open-label, single-dose, multi-site clinical trial evaluating GPH101 in approximately 15 participants with severe SCD.
  • GPH101 is an investigational next-generation gene-edited autologous hematopoietic stem cell (HSC) therapy designed to directly correct the genetic mutation that causes sickle cell disease (SCD).

Georgia State University Housing Summer Camps & Conferences and Intern Housing

Retrieved on: 
Thursday, December 9, 2021
Career, Centennial Park, Service, Internship, Heart, ADA, Learning, City, Business, Conference, Hospitality, CDC, Georgia, Intention, Safety, CNN Center, Organization, Forbes, Meal, ALL, Transport, Georgia Aquarium, Hartsfield–Jackson Atlanta International Airport, Community Care, Multimedia, Solution, Boston University Housing System, Hotel

- one of Forbes Top 20 Cities for Business and Careers -Georgia State University Housing is your affordable option for all conferences, meetings, trainings, summer camps, long term internship housing, short term transient accommodations and citywide event overflow accommodations.Additional services include registration/event management, meeting and classroom space, catering and meals, audio/visual, transportation and much more!

Key Points: 
  • - one of Forbes Top 20 Cities for Business and Careers -Georgia State University Housing is your affordable option for all conferences, meetings, trainings, summer camps, long term internship housing, short term transient accommodations and citywide event overflow accommodations.Additional services include registration/event management, meeting and classroom space, catering and meals, audio/visual, transportation and much more!
  • BE IN THE CENTER OF IT ALL, IN DOWNTOWN ATLANTA
    Enhance your event, conference, or internship experience by reserving space through Georgia State University Conference Services.
  • Interns with programs in the metro-Atlanta area can experience the best the city has to offer with our Summer Intern Housing.
  • Georgia State University Conference Services provides first-class housing with an array of amenities and an unbeatable location.

Reunion Rehabilitation Hospital Phoenix Names Ayo Ayodele Chief Therapy Officer

Retrieved on: 
Wednesday, December 8, 2021
Beijing, Administration, Health, GLOBE, Rehabilitation, Comanche County, Hospital, Georgia Institute of Technology School of Physics, Patient, CEO, GBSB Global Business School, Syracuse University, Utica College, Integris Health, Physical medicine and rehabilitation, Ayodele, Goal, Peking University, CTO, Lists of diseases, Georgia, Healthcare

PHOENIX, Ariz., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Reunion Rehabilitation Hospital Phoenix today announced Ayo Ayodele as its new Chief Therapy Officer (CTO). Ayodele, a physical therapist of 20 years, has held roles as a clinician and executive across a variety of different sites of care.

Key Points: 
  • PHOENIX, Ariz., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Reunion Rehabilitation Hospital Phoenix today announced Ayo Ayodele as its new Chief Therapy Officer (CTO).
  • As the CTO, Ayodele manages overall operations in Reunion Phoenixs therapy department, ensuring high-quality, cost-effective delivery of patient care; managing therapy personnel; and developing and implementing approved therapy department projects and goals.
  • Prior to joining the Reunion Phoenix team, Ayodele served as the Administrative Director of Rehabilitation Services with Integris Health at Comanche County Memorial Hospital.
  • Reunion Rehabilitation Hospital Phoenix, located in downtown Phoenix, is designed to provide comprehensive, high-quality post-acute medical rehabilitation therapies to a wide variety of patients.

Ultra Resources Inc. Closes First Tranche of Private Placement for Gross Proceeds of C$3.6 Million

Retrieved on: 
Tuesday, December 7, 2021
Company, GLOBE, Income Tax Act, Gold, Income Tax Act 1967, Foreign Investment in Real Property Tax Act, Lithium, TSX Venture Exchange, Securities Act of 1933, News, NFT, Private, Offering, Regulation, Sale, Acquisition, Person, Private placement, Georgia, Security (finance)

VANCOUVER, British Columbia, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Ultra Resources Inc. (TSX-V: ULT) (Ultra Resources or the "Company") is pleased to announce that it has closed the first tranche of its previously announced private placement (the Private Placement) for gross proceeds of C$3,626,899.

Key Points: 
  • VANCOUVER, British Columbia, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Ultra Resources Inc. (TSX-V: ULT) (Ultra Resources or the "Company") is pleased to announce that it has closed the first tranche of its previously announced private placement (the Private Placement) for gross proceeds of C$3,626,899.
  • Each NFT Unit consists of one common share of the Company (each, a NFT Share) and one half of one Warrant.
  • Finders fees of C$242,889.46 were paid and 660,227 finders warrants were issued in connection with the Private Placement.
  • Ultra Resources is an exploration and development company with a focus on the acquisition and development of lithium, gold, and copper assets.

Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021

Retrieved on: 
Monday, December 6, 2021
Health, Genetics, Other Health, Other Science, Research, Science, Biotechnology, Investor, Efficacy, Review, Patient, CAR, Infection, Allotransplantation, ID, Precision, List, Gene editing, Georgia World Congress Center, CD19, Public, Congress Center, Abstract, Nasdaq, 2021 Essex County Council election, Hematology, Genome, Society, ASH, Georgia, Webcast, Vaccine

This event is not an official program of the ASH annual meeting.

Key Points: 
  • This event is not an official program of the ASH annual meeting.
  • The dial-in conference call numbers for domestic and international callers are (866) 996-7202 and (270) 215-9609, respectively.
  • Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS genome editing platform.
  • ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.

NRx Announces Completion of Data Safety Meeting for Phase 2 Trial of BriLife Vaccine, Phase 2b/3 Registration Trial to Begin in Nation of Georgia, Israel, European Union, and Other Regions

Retrieved on: 
Monday, December 6, 2021
Nasal cavity, Lung, World Health Organization, Cell, National Security Advisor (United States), BARDA, JD, Immunity, GLOBE, Letter, Development, World, Israel Institute for Biological Research, Immune system, Human services, Food, COVID, CEO, Georgia, United States Army, European Medicines Agency, Biomedical Advanced Research and Development Authority, National, Biology, Cherokee Nation v. Georgia, Health, MPH, Vaccine, Goal, Cromos, Omicron, LLC, J&J, Fast Track, FDA, Patient, Adoption, Dark Enlightenment, US Foods, Breakthrough therapy, Novartis, ASPE, COVID-19, Lilly, Data monitoring committee, NASDAQ, Pharmaceutical industry

Based on the input received, NRx is proceeding with its plans to initiate a phase 2b/3 registration trial of BriLife (see www.clinicaltrials.gov NCT04990466).

Key Points: 
  • Based on the input received, NRx is proceeding with its plans to initiate a phase 2b/3 registration trial of BriLife (see www.clinicaltrials.gov NCT04990466).
  • NRx, working in concert with Cromos, LLC has received guidance in design of the trial from the European Medicines Agency and the World Health Organization.
  • The BriLife 002 phase 2b/3 trial is expected to commence in Israel and the Nation of Georgia, with European and North American countries to be added once the initial phase 2b volunteers have been vaccinated.
  • The trial configuration will be a non-inferiority design comparing BriLife to an already approved vaccine.

Adverum Biotechnologies Appoints Rupert D’Souza, Ph.D., M.B.A. as Chief Financial Officer

Retrieved on: 
Monday, December 6, 2021
Patient, Private Securities Litigation Reform Act, Genentech, History of Indian Institutes of Technology, Â, Eye, Georgia, Nasdaq, Leadership, University, Business, BioMarin Pharmaceutical, Institute, Chemical engineering, AMD, GLOBE, LLC, CFO, Biomolecular engineering, Accounting, University of Chicago Booth School of Business, Doctor of Philosophy, Employment, Degenerative disease, Georgia Tech, Management, Pharmaceutical industry

Dr. DSouza will serve as a member of Adverums executive committee and will report to Laurent Fischer M.D., president and chief executive officer at Adverum Biotechnologies.

Key Points: 
  • Dr. DSouza will serve as a member of Adverums executive committee and will report to Laurent Fischer M.D., president and chief executive officer at Adverum Biotechnologies.
  • On behalf of the entire company, I am delighted to welcome Rupert to Adverum and look forward to partnering with him as we advance the companys strategy together, said Dr. Laurent Fischer, president and chief executive officer at Adverum Biotechnologies.
  • I was drawn to Adverum by the companys potential transformative gene therapy treatments for ocular and rare diseases, said Rupert DSouza, Ph.D., M.B.A., chief financial officer of Adverum Biotechnologies.
  • Prior to Replay Holdings, Dr. DSouza was the founder and chief financial officer consultant at RMND LLC, a business development agency.

GCP Applied Technologies Signs a Definitive Agreement to Be Acquired by Saint-Gobain

Retrieved on: 
Monday, December 6, 2021
Private Securities Litigation Reform Act, THE, Security (finance), Coronavirus, Securities Act of 1933, Annual report, Forward-looking statement, Compliance, GCP, Georgia, Lakeview Parkway (Utah County, Utah), Weather, SEC, Proxy, Compagnie Française d'Assurance pour le Commerce Extérieur, Tripura Merger Agreement, U.S. Securities and Exchange Commission, Nature, COVID-19, Lists of disasters, Securities Exchange Act of 1934, Research, Communication, Risk, Annual, Public health, Person, Attention, Failure, Growth, Bank

A special meeting of the stockholders of GCP will be announced as promptly as practicable to seek stockholder approval in connection with the proposed Merger.

Key Points: 
  • A special meeting of the stockholders of GCP will be announced as promptly as practicable to seek stockholder approval in connection with the proposed Merger.
  • GCP expects to file with the Securities and Exchange Commission (SEC) a proxy statement and other relevant documents in connection with the proposed Merger.
  • The definitive proxy statement will be sent or given to the stockholders of GCP and will contain important information about the proposed transaction and related matters.
  • INVESTORS AND STOCKHOLDERS OF GCP ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND OTHER RELEVANT MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT GCP, PARENT, MERGER SUB, GUARANTOR AND THE MERGER.